RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 6 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > It’s the Law: Recent Changes in the EU SmPC Guideline

It’s the Law: Recent Changes in the EU SmPC Guideline

Posted 01 December 2010 | By

Product information in the EU comprises the Summary of Product Characteristics (SmPC),1 the Patient Information Leaflet (PIL) and labeling on the primary and secondary containers. The PIL contains information on the product's use written in layman's terminology. The SmPC, the prescriber's information leaflet, includes more details on product characteristics, safe and effective product use and clinical and nonclinical trial results. The SmPC is an integral part of the marketing authorization and sets out the agreed position of the medicinal product as determined during the assessment process between the Competent Authority and the applicant. It cannot be changed without approval from the Competent Authority. This article points out and discusses recent major revisions in the SmPC guideline.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.